Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw(Massachusetts General Hospital), Enriqueta Felip(Vall d'Hebron Institute of Oncology), Todd M. Bauer(Tennessee Oncology), Benjamin Besse(Institut Gustave Roussy), Alejandro Navarro(Vall d'Hebron Institute of Oncology), Sophie Postel‐Vinay(Université Paris-Sud), Justin F. Gainor(Massachusetts General Hospital), Melissa L. Johnson(Sarah Cannon), Jörg Dietrich(Massachusetts General Hospital), Leonard P. James(Pfizer (United States)), Jill S. Clancy, Joseph Chen(Pfizer (United States)), Jean‐François Martini(Pfizer (United States)), Antonello Abbattista(Pfizer (Italy)), Benjamin Solomon(Peter MacCallum Cancer Centre)
The Lancet Oncology
October 23, 2017
10.1016/s1470-2045(17)30680-0
Cited by 648Open Access
Full Text

Abstract

Related Papers

No related papers found

Powered by citation graph analysis